{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:01:17Z","timestamp":1763704877197},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T00:00:00Z","timestamp":1383177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>This study investigated whether biochemical parameters add predictive information concerning risk for weight gain associated with treatment with atypical antipsychotics (<jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content>) to that provided by baseline weight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Weight changes were assessed in 25 patients with schizophrenia after 3\u20136 months of treatment. These patients were started on <jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content> monotherapy owing to a first psychotic episode or resumed treatment after at least a 6\u2010month period of abandonment. Anthropometric and biochemical data were collected and analyzed as predictors of early weight change.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The baseline biochemical and anthropometric data were not significantly higher in the patients than in the healthy participants. During follow up, the patients had significant increases in body mass index and total cholesterol and apolipoprotein <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> level. The baseline weight and leptin level were predictive of weight gain during follow up, with an inverse association in both cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Baseline weight and leptin level may help to assess the risk of early weight gain with <jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pcn.12110","type":"journal-article","created":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T10:53:56Z","timestamp":1383216836000},"page":"127-132","source":"Crossref","is-referenced-by-count":15,"title":["Contribution of baseline body mass index and leptin serum level to the prediction of early weight gain with atypical antipsychotics in schizophrenia"],"prefix":"10.1111","volume":"68","author":[{"given":"Benjam\u00edn","family":"Cort\u00e9s","sequence":"first","affiliation":[{"name":"Psychiatry Service University Hospital of Salamanca  Salamanca"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joemir","family":"B\u00e9cker","sequence":"additional","affiliation":[{"name":"Psychiatry Service University Hospital of Salamanca  Salamanca"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Mories \u00c1lvarez","sequence":"additional","affiliation":[{"name":"Endocrinology Service University Hospital of Salamanca  Salamanca"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana I. S\u00e1nchez","family":"Marcos","sequence":"additional","affiliation":[{"name":"Endocrinology Service University Hospital of Salamanca  Salamanca"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Molina","sequence":"additional","affiliation":[{"name":"Salamanca Biomedical Research Institute (IBSAL)  Salamanca"},{"name":"Psychiatry Department University of Valladolid  Valladolid Spain"},{"name":"Clinic Hospital of Valladolid Psychiatry Service University of Valladolid  Valladolid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,31]]},"reference":[{"issue":"23","key":"e_1_2_6_2_1","first-page":"5","article-title":"Review of atypical antipsychotics and weight gain","volume":"62","author":"Sussman N","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_6_3_1","first-page":"23","article-title":"Early predictors of weight gain risk during treatment with olanzapine: Analysis of pooled data from 58 clinical trials","volume":"42","author":"Lipkovich I","year":"2009","journal-title":"Psychopharmacol. Bull."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2009.00589.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00431-0"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318172b8e6"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.11.026"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1100425"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/YPG.0b013e3283328e06"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1280793"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340503"},{"key":"e_1_2_6_12_1","volume-title":"Obesity: Preventing and Managing the Global Epidemic","author":"World Health Organization","year":"2000"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0204"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0924-977X(95)80001-I","article-title":"Weight gain induced by clozapine","volume":"5","author":"Hummer M","year":"1995","journal-title":"Eur. Neuropsychopharmacol."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0404"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2008.11.001"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181fae248"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800783"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000227705.56870.06"},{"key":"e_1_2_6_20_1","first-page":"1001","article-title":"Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects","volume":"24","author":"Wen F","year":"2003","journal-title":"Acta Pharmacol. Sin."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0417"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.113"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.09.013"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2008.095"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2006.03.001"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.2.140"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/10401230802017050"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.11.009"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpcn.12110","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.12110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T18:51:48Z","timestamp":1696186308000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.12110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,31]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/pcn.12110"],"URL":"https:\/\/doi.org\/10.1111\/pcn.12110","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,31]]}}}